Clinical Trial Update: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating subcutaneous recombinant human IL-15 in combination with alemtuzumab for refractory or relapsed adult T-cell leukemia and related T-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Leukemia
• T-cell Lymphoma Relapsed
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• subcutaneous recombinant human IL-15 (recombinant human interleukin-15)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL) | Phase 1 | Status: COMPLETED | Results posted: 2022-04-29